Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
Key claim: The FDA has classified hyperoxia monitoring devices used alongside pulse oximeters as class II medical devices with special controls, giving manufacturers a clearer and less burdensome path to market them.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the hyperoxia monitoring device adjunct to pulse oximetry into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the hyperoxia monitoring device adjunct to pulse oximetry. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
Class II classification with special controls lets manufacturers of hyperoxia monitors clear FDA via 510(k) rather than the more burdensome Class III premarket approval, which generally speeds availability of adjunctive oxygen-level monitoring tools in clinical settings. For patients and clinicians using pulse oximetry, it formalizes a regulatory category for devices meant to flag excess oxygen alongside standard oximetry readings.